Keynote Financial Services LLC Takes $1.77 Million Position in Pfizer Inc. (NYSE:PFE)

Keynote Financial Services LLC bought a new position in Pfizer Inc. (NYSE:PFE) during the first quarter, according to its most recent filing with the SEC. The firm bought 63,613 shares of the biopharmaceutical company’s stock, valued at approximately $1,765,000. Pfizer makes up 1.5% of Keynote Financial Services LLC’s investment portfolio, making the stock its 13th largest holding.

Several other hedge funds have also bought and sold shares of the business. Creekmur Asset Management LLC bought a new stake in Pfizer during the fourth quarter worth $32,000. Trivant Custom Portfolio Group LLC lifted its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares in the last quarter. Tennessee Valley Asset Management Partners purchased a new position in Pfizer during the fourth quarter worth about $36,000. DiNuzzo Private Wealth Inc. bought a new stake in Pfizer in the 4th quarter worth about $37,000. Finally, ESL Trust Services LLC purchased a new stake in Pfizer in the 1st quarter valued at about $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PFE. UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Barclays boosted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday. Eight investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $34.58.

Pfizer Stock Performance

NYSE:PFE traded down $0.22 on Friday, reaching $30.43. 42,364,712 shares of the company’s stock were exchanged, compared to its average volume of 37,871,120. The firm has a market cap of $172.43 billion, a price-to-earnings ratio of -507.08, a P/E/G ratio of 1.07 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a fifty day simple moving average of $28.73 and a 200-day simple moving average of $27.84. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.19.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.31%. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the firm earned $0.67 EPS. Pfizer’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.52%. Pfizer’s payout ratio is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.